Targeting the de novo lipogenesis pathway as a potential therapy for liver cancer
Speaker: James Lally Research Associate
Dr. Lally is a Research Associate in the Department of Medicine at McMaster University in the laboratory of Dr. Gregory Steinberg. He earned his PhD at the University of Guelph studying exercise and insulin resistance in skeletal muscle tissue, followed by a Postdoctoral Fellowship with Dr. Steinberg with research focused on the relationship between obesity-related disorders, including NAFLD, and the development of liver cancer.
- Non-alcoholic fatty liver disease (NAFLD) as an emerging risk factor for liver cancer
- Acetyl-CoA Carboxylase (ACC) inhibition as a potential drug target for treating liver cancer
- Current preclinical models for NAFLD and liver cancer
Genetic target validation of ACLY as a lipid metabolic regulator of hepatocellular carcinoma progression
Speaker: Jianhan Wu MSc. Candidate
Jianhan completed his BHSc degree from McMaster University in 2018. He is currently an MSc student under the supervision of Dr. Gregory Steinberg. His work involves phenotypic characterization of ACLY through a gene silencing approach in the context of hepatocellular carcinoma.
- Overview of the role of lipid metabolism in hepatocellular carcinoma
- Highlight existing evidence supporting ACLY as an anti-cancer therapeutic target
- Elucidate the effects of ACLY genetic knockdown in vitro using Hep3B and SK-Hep1 cell lines and in vivo using an orthotopic immune-compromised mouse model